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1SUMMARY
Leukemia is a group of diseases characterized by abnormal and
uncontrolled proliferation of haemopoietic cells cause progressively increasing
infiltration of the bone marrow. Acute lymphoblastic leukemia (ALL) occurs
when there is an acquired damage to the DNA of a single cell in the bone
marrow. It results in extensive and uncontrolled growth and accumulation of
lymphoblast or leukemic blast, which do not function as normal blood cells.
Moreover, it causes the blockage of the production of normal marrow cells and
deficiencies in erythrocytes (anemia), platelets (thrombocytopenia) and
leukocytes (in particular neutrophil). 6-MP is one of the cornerstones in ALL
chemotherapy. 6-MP is converted by TPMT to the inactive metabolite methyl
mercaptopurine. TPMT is known to catalyze S-methylation of aromatic and
heterocyclic compounds, preferentially thio compounds such as 6-MP and
6-TG. Genetic polymorphism of TPMT have been demonstrated to influence
drug metabolism and its effects, constituting one of the most studied and
significant example of association between drug clinical effects and a genetic
polymorphism. ITPA is a cytosolic enzyme which is involved in the metabolism
of 6-MP. It catalyzes the hydrolysis of inosine triphosphate (ITP) to inosine
2monophosphate (IMP), thereby recycling purines that might otherwise be
trapped in the form of ITP preference, thus protecting cells from the
accumulation of harmful nucleotides such as ITP and deoxyinosine
triphosphate. Genetic polymorphisms in the ITPA are associated with reduced
activity of the ITPA enzyme and increase toxicity to mercaptopurine.
In chapter 1, the current knowledge of leukemia and acute
lymphoblastic leukemia and their treatment were summarized. In this
chapter, I also summarized about TPMT and ITPA through literature
reviews.
In chapter 2, distribution of TPMT and ITPA polymorphism among
Bangladeshi children and their association with the adverse effects of 6-MP
in acute lymphoblastic leukemia (ALL) patients was identified. In this study, I
recruited 75 patients diagnosed with ALL and 75 volunteers with minor
illnesses. Genotyping for TPMT (TPMT*3C, *3B, *2) and ITPA (ITPA94C>.A)
was done. Relationship between genotypes and adverse effects of 6-MP was
3investigated. Minor allele frequency of TPMT*3B, TPMT*3C and ITPA
polymorphism among volunteers were 0.006, 0.020 and 0.903 and minor
allele frequency of TPMT*3C and ITPA polymorphism among ALL patients
were 0.010 and 0.153 respectively. ALL patients with TPMT*3C variant
developed leucopenia (P=0.037) neutropenia (P=0.017) and
thrombocytopenia (P=0.008). ITPA variant developed fever (P=0.003)
neutropenia (P=0.001) and liver toxicity (hyperbillirubinemia, P=0.048, and
raised serum ALT, P=0.007). These findings strongly suggest the importance
of TPMT and ITPA genotyping in patients with ALL to design more rational
and cost effective treatment strategy in children with ALL.
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CHAPTER 1
LITERATURE REVIEWS
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1.1 Leukemia
Leukemia was first observed by pathologist Rudolf Virchow in 1845.
Virchow called the condition leukemia in German, which he formed from the
two Greek words Leuokos, meaning “white” and aima, meaning “blood”.
Leukemia is a group of diseases characterized by abnormal and uncontrolled
proliferation of haemopoietic cells cause progressively increasing infiltration
of the bone marrow (haemopoietic blast cells constitute more than 30% of bone
marrow cell), although in certain forms the lymphatic tissues are particularly
affected. The process of differentiation in leukaemic cells in often abnormal
and this commonly results in an immature morphological appearance (1). The
major forms of leukemia are divided on the basis of their morphological
characteristics into four categories, i.e., acute and chronic myelogenous and
lymphocytic leukemia. Previously, being diagnosed as leukemia was
tantamount to receiving a death sentence, but now a day the majority of these
patients can be cured by chemotherapy, in combination with intensive
supportive care. Originally involving the use of a single drug, but recently
such chemotherapy is complex and multidisciplinary, involving combination of
chemotherapeutic agents. Despite the availability of effective treatment,
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leukemia remains the second major cause of death in children in western
world.
1.2 Acute lymphoblastic leukemia (ALL)
Acute lymphoblastic leukemia (ALL) occurs when there is a acquired
damage to the DNA of a single cell in the bone marrow. It results in extensive
and uncontrolled growth and accumulation of lymphoblast or leukemic blast,
which do not function as normal blood cells. Moreover, it causes the blockage of
the production of normal marrow cells and deficiencies in erythrocytes
(anemia), platelets (thrombocytopenia) and leukocytes (in particular
neutrophil). Leukemic cells can spread from bone marrow to the blood, lymph
nodes, spleen, liver, central nervous system and other organs. ALL remains
the most common cancer that occurs in childhood, accounting for
approximately 25% of all pediatrics malignancies and 75% of cases of
childhood leukemia. ALL can strike children of all ages but most likely to
occur before age of 5 years. The 5 year rate of event free survival for children
with ALL is nearly 80% (2, 3).
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1.2.1 Etiology of acute lymphoblastic leukemia
The etiology of acute leukemia is unknown. The following factors are
important in pathogenesis of leukemia:
1) Ionizing radiation
2) Chemicals (benzene)
3) Drugs (alkylating agents, radiation therapy)
4) Genetic consideration
a. Identical twins
b. Siblings – 4 times greater than that of general population
c. Chromosomal abnormalities such as down syndrome, bloom
syndrome, fanconi anemia (4)
1.2.2 Presenting manifestation of acute lymphoblastic leukemia
Common:
- Anemia
- Fever, malaise
- Haemorrhage, bruising, petechiae
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Less common:
- Infection of mouth and pharynx
- Pain sin bones and joints (childhood especially)
- Upper respiratory tract infection (childhood especially)
- Superficial lymph node enlargement (childhood especially)
Occasional:
- Abdominal pain
- Mediastinal obstruction (childhood especially)
- Nervous system abnormalities
- Skin rash
- Gum hypertrophy (1)
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1.2.3 Diagnosis of acute lymphoblastic leukemia (ALL)
a) Laboratories studies
i. Blood count
- Moderate to marked reduction of hemoglobin with normochromic
normocytic red cell morphology.
- The white blood cell count may be low, normal or increased in number.
- Blood smear usually shows very few to few blasts (in patient with
leucopenia). The WBC count is greater than 10,000/mm blasts are
usually abundant. Eosinophilia is occasionally seen in children with
ALL.
- 92% of patients have platelet count below normal (thrombocytopenia)
(5)
ii. Bone marrow investigation
- The hallmark of the diagnosis of ALL is the blast cells, relatively
undifferentiated cell with diffusely distributed nuclear chromatin, one
or more nucleolei and basophilic cytoplasm (5). Bone marrow is
usually replaced by 80 – 100 % blast cells. Megakaryocytes are usually
17
absent. Leukemia must be suspected when the bone marrow contains
more than 5% blasts.
iii. Immunophenotyping
- Monoclonal antibodies are used to differentiate ALL from AML (acute
myelocytic leukemia). A panel of B-and T-lineage markers and
lymphocytes maturation markers are used to sub classify ALL.
iv. Morphological classification
- According to the French-American-British (FAB), classification of
ALL.
- L1 – a small monomorphic type with small homogeneous blasts,
single inconspicuous nucleolus, regular nuclear outline; commonest
subtype.
- L2 – a large heterogeneous type, larger blast, pleomorphic and
multinucleolate, irregular clefted nuclei with conspicuous nucleoli.
- L3 – Burkitt cell type – large homogenous blasts, abundant basophilic
cytoplasm with vacuoles; associated with B – cell phenotype (6).
v. Cytochemistry
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- ALL is frequently diagnosed by staining with Sudan black: ALL
negative, AML positive, enzymatic peroxides: ALL negative, AML
positive, and PAS: ALL positive, AML negative (5).
vi. Cytogenetics
- Specific chromosomal abnormalities are associated with distinct
subtypes of acute leukemia. It has major implications for the diagnosis
and management of acute leukemia and presence of cytogenetic
abnormalities in newly diagnosed patients with acute leukemia
provide important prognostic information (7).
1.2.4 Chemotherapeutic treatment of ALL
Chemotherapeutic treatment of ALL involves:
Phase I: Induction of remission with a combination of various drugs
like vincristine, prednisolone and L-asperginase often with daunorubicin and
cyclophosphamide.
Phase II: This is designed to take care of the small number of
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leukemic lymphoblast that remains after clinical remission is achieved.
Consolidation phase includes high dose systemic administration of drugs.
Phase III: A maintenance therapy to prevent relapse and to achieve
a total cure. Patients receive maintenance chemotherapy for further 2-3 years
with daily 6-MP, weekly methotrexate, monthly vincristine and prednisolone
(8). Duration of therapy varies among different protocols and centers.
Central nervous system therapy: This starts during the induction
phase and continues throughout therapy. This is designed to prevent to
relapse with leukemic meningitis.
Following intensive treatment for induction of remission and
subsequent consolidation, ALL patients usually receive maintenance therapy
for 2-3 years. A patient exhibits continuous and complete remission for a
period of 2.5 years. The risk of relapse usually occurs within one year after
cessation of therapy, is approximately 20%. So when the chemotherapy can be
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terminated most patients have been cured. Relapse usually occurs in the bone
marrow. It also may develop alone or even simultaneously in the central
nervous system. Even at this situation complete remission can still be
obtained in a small proportion of the patients, especially in children, by
combination therapy or bone marrow transplantation.
6-MP is one of the cornerstones in ALL chemotherapy. 6-MP,
6-thioguanine, and azathioprine are thiopurine drugs that are usually used to
treat acute lymphoblastic leukemia, autoimmune disorder, inflammatory
bowel disease and organ transplant recipient (9, 10). Both 6-MP and
6-Thioguanine are pro-drugs.
1.2.5 Survival rate of ALL patients
The children oncology group (COG) recently celebrated the
milestone of 50 years of pediatric clinical trials and collaborative research in
oncology. This group had its origin in the four legacy pediatric clinical trial
groups; the Children’s Cancer Group (CCG), the Pediatric Oncology Group
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(POG), the National Wilms’ Tumor Study Group (NWTS), and the Intergroup
Rhabdomyosarcoma Study Group (IRSGG), which merged in 2000 to form the
COG. In recent report from COG mentioned that, over the last 50 years, the
survival rates for childhood cancer have risen from 10% to 80%. Outcome on
ALL has gone from a 6-month median survival to an 80% over all cure rates
(11).
Figure 1.1: Survival of CCG patients with ALL 1968-1997 (11)
1.3 6-Mercaptopurine
a) Discovery of the drug: In 1942, George Hitchings set out to
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develop a treatment for cancer. He wanted to create chemicals that were
similar enough to normal nucleotides to be used in cells but different enough
to interfere with DNA synthesis. Gertrude Elion joined Hitchings in his quest
in 1944. 6-MP was originally synthesized by Elion and Hitchings in 1951 (12)
by replacement of oxygen atom at carbon 6 of hypoxanthin or guanine,
respectively, by sulfur.
Figure 1.2: Chemical structures of thiopurines and the corresponding
endogenous purines.
The first clinical trial with 6-MP involved oral administration and
demonstrated a beneficial effects in connection with treatment of acute
23
leukemia in children (13). Subsequently, extensive experience in the
administration of 6-MP was obtained and in the 1960’s this drug was
established as the backbone of orally administered maintenance therapy of
ALL (14).
In 1948, Elion, and Hitchings found that 6-Thioguanine effectively
inhibits the growth of both the bacterium Lactobacillus (L.) casei and tumors
in mice. Later, 6-TG was shown to produce good clinical remission of
granulocytic leukemia in 2 adults, although with severe side effects, including
nausea, vomiting, and suppression of the bone marrow (15). On the basis of
empirical evidence, 6-TG very soon became part of the routine treatment of
AML (16). Combination of 6-MP with MTX and steroids (the only drugs
available for treatment of acute leukemia at the time of introduction of
thiopurines) extended the median survival time from 3-12 months. Only 2
years after its original synthesis and the initial anti-microbiological
investigations, 6-MP was approved by authorities for use in the treatment of
childhood ALL (17).
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In 1958, Schwartz et al. (18) demonstrated the immunosuppressive
ability of 6-MP to prevent and antibody response in rabbit injected with an
antigen. Shortly thereafter, the Hitchings-Elion laboratory synthesize
numerous 6-MP derivatives, including azathioprine, a pro-drug that is
reduced non-enzymatically to 6-MP in vivo (10, 19). The first comparison of
azathiopurine and 6-MP as immune-suppressor was performed on 10 dogs
that had received renal transplant. AZA had better effects in this system (20)
and was soon found to be an effective immune-suppressive agent in human as
well (21).
Today, thiopurine are widely used to treat ALL of childhood,
inflammatory bowel disease and autoimmune diseases, as well as to prevent
rejection of organ transplant (22). These drugs, like many cytotoxic agents,
have relatively narrow therapeutic index, with potential life-threatening
drug-induced toxicity, primarily in the form of myelosuppression (23, 24). The
other major toxic effect of thiopurines is hepatotoxicity (25) which has been
reported to be related to the amounts of thioguanine nucleotides (TGNs), or
methylmercaptopurine (meMP) in erythrocytes and to the accumulation of
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6-MP and it’s metabolites in the liver (26). 6-MP is now used as a routine
component of all modern protocols for maintenance therapy of children with
ALL (23) and the combination of high-dose MTX and 6-MP is commonly
employed for consolidation therapy of childhood ALL (27).
1.3.1 Metabolism of 6-MP
6-MP is an inactive pro-drug that exerts cytotoxicity only after
intracellular metabolism to active metabolite (28). The bioavailability of 6-MP
is only 16 percent, because of high first-pass metabolism, after oral
administration, 6-MP undergoes extensive intestinal and hepatic metabolism
by aldehyde oxidase (AO) and xanthine oxidase (XO), which convert this
substance into rather inactive metabolites. Oxidation of 6-MP in the liver via
xanthin oxidase (XO), generates thiouric acid (TUA), and inactive metabolite
that is eliminated in the urine (29).
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Figure 1.3: Scheme of thiopurine drug metabolism. XO = xanthine oxidase,
HPRT = hypoxanthine phosphoribosyl transferase, TPMT = thiopurine
methyltransferase (30)
6-MP is converted by TPMT to the inactive metabolite methyl
mercaptopurine (meMP) (31). In a third metabolic route, 6-MP is initially
converted by hypoxanthine guanine phosphoribosyl transferase (HGPRT) to
6-thioinosine monophosphate (TIMP) and thioguanosine monophosphate
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(TGMP), respectively. Conversion of TIMP to TGMP via thioxanthine
monophosphate (TXMP) is catalyzed by two enzymes, IMP dehydrogenase
(IMPDH) and GMP synthatase (GMPS) respectively (32). Subsequent
reactions by phosphokinases wield 6-thioguanosine diphosphate and
triphosphate (TGDP and TGTP). TGMP, TGDP and TGTP are collectively
termed as thioguanine nucleotides (TGNS). In corporation of 6-TGDP into
DNA triggers cell cycle arrest and apoptosis by a process involving the
mismatch require (MMR) pathway (33). The enzyme, thiopurine
methyltransferase (TPMT) inactivates 6-MP through the formation of
methylmercaptopurine (34). 6-TGNs can be methylated by TPMT. 6-TIMP can
be methylated by TPMT to form 6-methyl thionosine 5-monophosphate
(6-MTIMP), 6-methyl thionosine 5’-diphosphate (6-MTIDP) and 6-methyl
thioinosine 5’-triphosphate (6-MTITP). The above mentioned last three
metabolites are called 6-methyl mercaptopurine ribonucleotides (6-MMPRS).
6-TIMP can also be phosphorylated by monophosphate kinase to produce
6-thioinosine 5’-triphosphate (6-TITP) and ultimately back to 6-TIMP by an
enzymatic reaction catalyzed by inosine triphosphate pyrophosphatase
(ITPase). Besides methylation of 6-MP to the inactive metabolite meMP,
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TPMT methylates TIMP to meTIMP, a metabolite that has been shown to
inhibit purine de novo synthesis (PDNS) (35).
1.4 Role of pharmacogenetics in drug toxicity and efficacy
Pharmacogenetics aims to use knowledge of genetic polymorphism
to ‘tailor’ therapy for improved response and reduced toxicity. The term
pharmacogenetics represents the study of genetic factors that influence
response to drugs and chemicals and was first termed in 1959 (36). Most
research so far has focused on single polymorphisms. A more comprehensive
approach to predict treatment response will be considered genetic variation in
entire biological and pharmacological pathways. Genetic variations are the
results of multiple mechanisms such as single nucleotide polymorphisms
(SNPs) are over 90%, insertion, deletion, tandem repeats, and microsatellites.
In an attempt to individualize therapy, pharmacogenetic is used in search for
answers to the hereditary basis of individual differences in drug response.
Some drugs require metabolism to be activated or inactivated. Some enzymes
involve in the biotransformation have polymorphic expression.
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Pharmacogenetic causes variability in the metabolism of MP (Fig 1.3), due to
polymorphic variation in the activity of TPMT enzyme (37).
Figure 1.4: Five stages of pharmacogenetics and pharmacogenomics in
cancer therapy (38).
1.5 Thiopurine methyltransferase (TPMT)
Thiopurine methyltransferase (TPMT) is a cytosolic enzyme present
in prokaryotes and eukaryotes. It has a molecular mass of 26 KDa, comprises
245 amino acids, is not metal dependent and TPMT is encoded by 34 Kb gene
consisting of 10 exons and 9 introns and has been localized to chromosome
6p22.3 (Fig 1.4) (39) found in the liver, kidneys, intestine, erythrocytes,
leukocytes and a number of other tissues.
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Fig 1.5: Position of TPMT gene on chromosome 6 (40)
TPMT is known to catalyze S-methylation of aromatic and
heterocyclic compounds, preferentially thio compounds such as 6-MP and
6-TG (18). The first study of the enzyme that catalyzed this reaction was
performed by Remy in the early 1960s using rodent tissue (41). At late 1970s,
TPMT activity was first assayed and studied in human tissue (42), with the
goal of testing the hypothesis that individual variation in this pathway for
thiopurine biotransformation might be related to individual differences in
drug toxicity and therapeutic efficacy. The first application of measurement of
RBC TPMT activity involved pharmacogenetic experiments performed with
large population samples and nuclear families (43). Those studies
demonstrated that the “trait” of level of RBC TPMT activity was controlled by
a common genetic polymorphism. The level of TPMT activity in erythrocytes
reflects the corresponding levels in the kidney, liver and lymphocytes (44, 45).
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Characterization and cloning of the human TPMT cDNA and gene expressed
that this phenotypic variations were from variation in the sequence of the
gene itself (46, 47). To date, at least a total of 23 such genetic polymorphism
have been identified which may be associated with decrease level of TPMT
enzyme activity or enhanced toxicity of thiopurine methyltransferase have
been identified (48).
1.5.1 Molecular basis for altered TPMT activity
The molecular basis of the TPMT polymorphism is largely related to
three common non synonymous coding single nucleotide polymorphisms (49),
each of which renders the protein unstable (47) and subject to enhanced
ubiquitination and degradation (50). TPMT enzymatic activity is controlled by
a common genetic polymorphism (49). So, the homozygous deficiency is
characterized by almost undetectable levels of TPMT protein; heterozygotes
have intermediate protein and activity levels and homozygous wild type
individuals have high levels of protein and activity (51, 52).
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There is pronounced inherited variations in TPMT activity, ranging
from high to virtually undetectable, were first observed in human tissues more
than two decades ago. The frequency of distribution of erythrocyte TPMT
activity in 298 control subjects was found to be trimodal. Approximately 1 in
300 individuals (0.3%) has low or undetectable level of this activity, which is
intermediate in approximately 10% of the general population (43).
1.5.2 Alleles of TPMT and genetic polymorphism
Variant human alleles associated with decreased catalytic activity of
TPMT involved point mutations in the open-reading frame or act intron/exon
splice sites. TPMT*1 is the wild-type allele, encodes the fully active enzyme;
wild TPMT*2 (238G4C), TPMT*3A (460G4A, 719A4G) and TPMT*3C
(719A4G) are the most prevalent accounting together for 80-95% of the
polymorphic alleles that lead to a significant reduction in enzyme activity (53).
TPMT*3B (460G4A) is less common and the remaining TPMT variant can be
considered to be family specific (‘private’) mutations found in individuals
belonging to various ethnic groups (54, 55, 56).
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Fig 1.6: Allelic variant of the TPMT gene. Boxes depict exons in the open
reading frame of the human TPMT gene. The positions of the three point
mutations detected by PCR-based assays and indicated (44).
1.5.3 Relationship between TPMT and 6-MP toxicity
There are many associations between single genetic polymorphisms
and drug effects have been clearly demonstrated, showing that inherited
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genomic variation causes substantial interindividual differences in drug
effects (57). Genetic polymorphism of TPMT have been demonstrated to
influence drug metabolism and its effects, constituting one of the most studied
and significant example of association between drug clinical effects and a
genetic polymorphism (58). TPMT polymorphism is inherited as an autosomal
co-dominant genetic trait. The enzymatic activity of TPMT shows a trimodal
distribution of high, intermediate and very low activity among the population
(43, 59). 89-94% of all individuals studied having a high activity, 6-11% having
intermediate activity and 0.3% having a very low or non-detectable activity
(47, 60).
Polymorphic variants of the TPMT gene encode enzymes which have
significantly reduced activity. Approximately 0.3% are homozygous for
non-functional alleles and the consequence absence of TPMT activity is
associated with severe thiopurine-induced hematological toxicity and bone
marrow suppression (61). Leucopenia, thrombocytopenia or any combination
of these may occur in bone marrow suppression
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Inactive TPMT alleles screening can be done to identify individuals
at risk of bone marrow toxicity. In case of homozygous-TPMT deficient
patients (two non-functional alleles), dose reductions are required to avoid the
life threatening bone marrow suppression (62). Heterozygous allele with a low
activity identifies the patients in whom lower doses of thiopurine can be used
safely. If a patient has clinical or laboratory evidence of myelosuppression,
TPMT testing should be considered (62). Approximately 90% dose reduction is
required for patients with the homogeneous mutations and 40% of dose
reduction may be required for patient with heterogeneous mutant.
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Table 1.1: TPMT genotype classification and implications to therapy
Genotype Activity Level Frequency in
the population
Dose Adjustments
Wild type High TPMT
activity
89% Start at normal
dose, may need to
increase
Heterogeneous
Mutant
Intermediate
TPMT activity
11% Start at 60% of
normal dose *
Homogeneous
Mutant
TPMT deficiency 0.33% Start at <10% of
normal dose **
* Children’s Oncology Group, 2008 (64)
**Weinshiboum and Sladek (43)
1.5.4 Ethnic variation in TPMT mutations
Although the overall prevalence of TPMT deficiency is similar
between different ethnic groups, the frequency of variant alleles differs
between different populations, for example, there is a higher representation of
the TPMT*3A allele in South Asian compared with the high frequency of the
TPMT*3C in East and West African (63). The TPMT*1 (wild-type allele, 96%)
and TPMT*3A (460G>A and 719A>G, 4%) alleles are most common among
Caucasians (65).
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1.5.5 Frequency of TPMT allele distribution in different populations
Several studies aimed at determining the allelic variations of the
TPMT in different populations. Some of these are summarized in following
table.
Table 1.2: Summary of different studies of TPMT allele variation in different
populations
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1.6 Inosine triphosphate pyrophosphatase (ITPA)
ITPA is a cytosolic enzyme which is involved in the metabolism of
6-MP. It catalyzes the hydrolysis of inosine triphosphate (ITP) to inosine
monophosphate (IMP), thereby recycling purines that might otherwise be
trapped in the form of ITP preference, thus protecting cells from the
accumulation of harmful nucleotides such as ITP and deoxyinosine
triphosphate. Genetic polymorphisms in the ITPA are associated with reduced
activity of the ITPA enzyme and increase toxicity to mercaptopurine (66).
Deficiency of inosine triphosphate pyrophosphatase (ITPAse) causes
accumulation of potentially toxic metabolite 6-thio-ITP (67). ITPase deficiency
is polymorphic, 5% of a normal population had decreased ITPase activity
which was shown in an early population study (68). High level of endogenous
ITP is accumulated in the red cells of completely ITPase deficient individuals,
was first demonstrated by Vanderheiden in 1965 (69). ITPase deficiency has
not been associated with any disease or clinical condition. It was suggested
that ITPase deficient patients would be at risk of suffering from side effects
when treated with purine drug analogues such as thiopurines (70).
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1.6.1 Structure of ITPA
Gen Bank accession number is A F026816 for ITPA gene. It is located
on the short arm of chromosome 20 (20P13) (71). The genomic structure of the
ITPA gene was determined by Sumi et al (72). ITPA gene consists of eight
exons and is ~ 13Kb long. 2 allelic variances in the ITPA gene were associated
with decreased ITPase enzyme activity. ITPA c.94C>A (P32) in exon 2, and
ITPA g.IVS2 + 21A>C (73). Zero rate cell enzyme activity was found in
homozygotes, whereas 22.5% enzyme activity was found in heterozygotes (74).
A C198A transversion (rs1127354) causing a proline to threonine replacement
at codon 32 (P32T polymorphism) is the most relevant SNP determining low
ITPA enzymatic activity (75, 76). ITPA94C>A transversion causes and amino
acid change (P32T), reducing ITPA enzymatic activity to 25% in heterozygotes,
and abolishing it in homozygous variants (77). Five single polymorphic
sequence variants in the human ITPA gene have been identified, two of which
are associated with ITPase loss of activity (94C>A in exon-2, and
IVS2+21A>C). These interact and affect branch points resulting in misplacing
of exons 2 and 3 leading to shortening of polypeptide stretches in the enzyme
(74). The other three coding region ITPA polymorphic sequence variants are
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silent mutations (138G>A, 561G>A and 708G>A) (72).
1.6.2 Ethnic variation in ITPA allele
Homozygosity of the ITPA 94A allele, which results in deficiency of
ITPase activity in erythrocytes and lymphocytes, occurs in approximately 1 in
1000 Caucasians (73). Carriers represent about 1 in 15 (6.0%) of Caucasian
populations, and have an average red cell ITPase activity of about 22% of
normal. This allele is more common in Asian populations, with a frequency of
11-15% (78). Homozygosity of the ITPA IVS2+21C allele occurs in
approximately 1 in 250 Caucasians, with a carrier frequency of about 1 in 8
(13.0%), resulting in partial reduction of ITPase activity with an average of
60% normal levels in red cells. Its frequency varies greatly in other
populations, e.g. the SNP is absent among Japanese. Compound heterozygotes
(ITPA 94A/IVS2+21C) have 10% of normal activity (79).
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1.7 Survival rate of TPMT and ITPA polymorphism
Genetic variations in the drug metabolisms are known to influence
treatment related toxicity and survival rate. TPMT is one of the most well
defined genotype of those. TPMT deficient individuals form higher
concentration thioguanine nucleotides and are more susceptible to acute
thiopurine toxicity such as myelosuppression (80). However, TPMT is more
frequent among Caucasians. There is a significant ethnic difference in
survival of TPMT and ITPA among Caucasians and Asian. Until now, most of
the studies belong to Western countries but a recent report from Korea shown
that ITPA variants were the only risk factor for lower event free survival
(EFS) which was 95.2% in wild type and 81.9% in AC/AA variant (HR 4.96,
95% CI =1.1-22.7, P=0.039) (81).
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CHAPTER 2
Polymorphism of TPMT and ITPA and adverse
effects of chemotherapy for acute lymphoblastic
leukemia children in Bangladesh
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2.1 Summary
This study was to identify the distribution of TPMT and ITPA
polymorphism among Bangladeshi children and their association with the
adverse effects of 6-MP in acute lymphoblastic leukemia (ALL) patients.
Pharmacogenetics approach reduces the toxicity and increases safety of
chemotherapy. 6-mercaptopurin (6-MP) metabolizing enzyme such as
thiopurine S-methyltransferase (TPMT) and inosine triphosphate
pyrophosphatase (ITPA) have contribution to variables responses including
adverse effects among patients treated with 6-MP in leukemia.
In this study, I recruited 75 patients diagnosed with ALL and 75
volunteers with minor illnesses. Genotyping for TPMT (TPMT*3C, *3B, *2)
and ITPA (ITPA94C>.A) was done. Relationship between genotypes and
adverse effects of 6-MP was investigated. Minor allele frequency of TPMT*3B,
TPMT*3C and ITPA polymorphism among volunteers were 0.006, 0.20 and
0.903 and Monir allele frequency of TPMT*3C and ITPA polymorphism among
ALL patients were 0.010 and 0.153 respectively. ALL patients with TPMT*3C
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variant developed leucopenia (P=0.037) neutropenia (P=0.017) and
thrombocytopenia (P=0.008). ITPA variant developed fever (P=0.003)
neutropenia (P=0.001) and liver toxicity (hyperbillirubinemia, P=0.048, and
raised serum ALT, P=0.007). In univariate logistic regression analysis, it was
observed that ITPA polymorphism had 6 times higher chance of absolute
neutropenia (OR = 6.25, 95%CI = 2.01 – 19.42), 3 times higher chance of
hyperbillirubinemia (OR = 3.58, 95% CI = 1.21 – 10.61), 4 times higher chance
of increase ALT (OR = 4.53, 95% CI = 1.53 – 13.43) and 7 times higher chance
of fever (OR = 7.00, 95% CI = 2.05 – 23.84) in compare to non-polymorphic
patients. After adjusted with age, sex, height and weight in multivariate
logistic regression analysis the association remained similarly significant.
In conclusion, this study strongly suggests the importance of TPMT
and ITPA genotyping in patients with ALL to design more rational and cost
effective treatment strategy in children with ALL.
55
2.2 Introduction
The treatment of pediatric acute lymphoblastic leukemia (ALL), the
most common malignancy in children, has reached success rates up to 90% in
the last 2 decades (1) in the western countries and some industrialized
countries. Whereas supportive care plays an important role during
chemotherapy for childhood malignancy to avoid/manage complications,
pharmacogenetical intervention has been a new approach to get not only a less
side effects but also better treatment outcome (2). 6-MP is one of the most
widely used and highly effective chemotherapeutic agent for maintenance
therapy in childhood ALL (3, 4). In the standard treatment, 6-MP is
administered as a daily oral dose, usually 1-2 years of maintenance therapy.
It has been found that, in pharmacogenetic studies among childhood ALL have
associated toxicity of 6-MP with single nucleotide polymorphisms (SNP) in
genes coding for 6-MP metabolizing enzyme such as thiopurine
S-methyltransferase (TPMT) and inosine triphosphate pyrophosphatase
(ITPA) (5). Pharmacogenetics provided a molecular approach which guides the
individualization of chemotherapy. This approach may reduce the toxicity and
increases safety of the therapy (5)
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Inosine triphosphatase catalyses the hydrolysis of ITP to inosine
monophosphate, thereby purines is trapped in the form of ITP (6, 7).
Deficiency of Inosine triphosphate pyrophosphohydrolase (ITPAse) has been
reported to cause accumulation of the potentially toxic metabolite 6-thio-ITP
(8). At least 5 variants of ITPA gene have been identified, among them two
single nucleotide polymorphisms of ITPA c.94C>A and ITPA g.IVS2+21A>C
are associated with decreased enzyme activity (9). Individual who are
homozygous for ITPA c.94C>A (P32T) mutation have total deficiency of
enzyme activity which accumulate ITP intracellularly whereas ITPA c.94C>A
heterozygotes have decreased ITPA activity that is 22.5% of control mean
value (7).
6-MP is an inactive pro-drug, which requires to go under metabolism
process into thioguanine nucleotides (TGN) in order to perform its cytotoxic
effects (10). TPMT is involved in the methylation reactions of 6-MP, it means
TPMT is a key enzyme in the metabolism of 6-MP. The activity of TPMT is
influenced by genetic polymorphism which can alter the rate of metabolism of
6-MP (11). The cellular accumulation of TGN is inversely related to TPMT
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activity; presumably the high TPMT activity shunts more drugs down the
methylation pathway, leaving less for activation to TGNs (10). Studies have
found that the distribution of TPMT activity in erythrocytes (RBC) to be
tri-modal; approximately 90% of persons have high activity, 10% have
intermediate activity, and 0.3% have less or not detectable enzyme activity (10,
12). Three of these alleles (TPMT*2, *3B and *3C) account for 80-95% of
intermediate or low enzyme activity cases (13, 14). The cumulative incidence
of 6-MP dose reduction due to toxicity was highest among patients who were
homozygous mutant for TMPT (TPMT *2/*3C/*3B), intermediate among
heterozygous patients and lowest among wild type (TPMT *2/*3C/*3B)
patients (15, 16).
In the treatment of ALL, the knowledge of SNPs in 6-MP metabolizing
enzymes and its related drug toxicity has developed more rational approaches
to optimize chemotherapy. TPMT and ITPA genetic variant differ from patient
to patient and among different ethnic. Determination of the frequency of this
genetic variant is necessary to consider the use of pharmacogenetic as a tool to
improve treatment outcome. Until now,there is no available report among
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Bangladeshi children about the incidence of TPMT and ITPA common allelic varients
and the relevance of those alleles on toxicities in patients with ALL. Thus the aim of this
study was to determine the frequency of TPMT and ITPA variant alleles among
Bangladeshi population and the association of polymorphisms with adverse effects of
6-MP.
2.3 Rational of the study
Bangladesh shows recent advances in relation to manage infectious
diseases (17), the chronic diseases in particular cancers are less prioritized.
The status of cancer in this country is not clearly known, as there is no
population-based cancer registry or national cancer registry of any kind.
According to WHO, Bangladesh is experiencing increasing cancer burden with
estimated 122,715 new cancer cases in 2012 (18). The number of new cases is
projected to be increased by 77% in 2030. These WHO estimate may not reflect
the real cancer status, as the estimate was extrapolated based on the
incidence and mortality rates from regional data (18). The figures are likely to
be underestimated as many cases go unreported due to lack of awareness,
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education, misconception, and poverty among populations, in addition due to
poor health system and poor governance (19). Moreover, overall cancer care
and management system are below international standard due to high
treatment cost, lack of oncologist and insufficient infrastructure.
In Bangladesh, pediatric tumors consist of 4.4% of all malignancies
during 2005 to 2009. Leukemia constituted about 14.3% of all childhood
malignancies; among them ALL were commonly found (20). The relative
incidence of malignancies seen at BSMMU in 2012 was acute lymphoblastic
leukemia 58%, non-hodgkin lymphoma 11% and acute myeloblastic leukemia
10%, neuroblastoma 5%, hepatoblastoma 3.5%, hodgkins lymphoma 3%,
Wilm’s tumor 2%, retinoblastoma 2%, germ cell tumor 2%, histocytosis 2%,
central nervous system tumor 1%, osteosarcoma 1% (21). Bangladesh has only
one state-run specialist cancer hospital, fourteen oncology units of public
medical teaching hospitals and few private clinics and hospitals are available
to treat cancer patients. While over 70% population live in the rural areas but
most of the tertiary care hospitals are situated in the central part of Dhaka,
Bangladesh (22).   Even though some cancer research has been started now a
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days, but most of them are based on the prevalence and risk factors.
Chemotherapic treatment is available but there is no scope of dose adjustment.
Still there is lack of research in Bangladesh regarding Chemotherapic toxicity
and their genetic cause and also how to minimize them. That’s why I
conducted this study to know the genetic polymorphism and toxicity of
Chemotherapic treatment in Bangladesh. Results of this research will guide
physician to the importance of prior diagnosis of genetic polymorphism, so
that they can adjust dose and minimize toxicity. As a result, continuation of
treatment and better prognosis will be expected.
2.4 Methods
This is a retrospective study conducted in two tertiary level hospitals in
Dhaka city, central part of Bangladesh. Seventy-five patients diagnosed with
acute lymphoblastic leukemia (ALL) recruited from pediatric hematology and
oncology department of Bangabandhu Sheikh Mujib Medical University
(BSMMU) and 75 children who attended in the outdoor department of Central
Hospital Limited who were presented with minor diseases other than cancer
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such as cold, diarrhoea or other minor illness have been recruited in this study.
All children had been suffering from ALL were under maintenance therapy
using 6-mercaptopurine 75mg/m2/day orally as per UKALL 2003protocol,
version 7 (23). All patients and volunteers were recruited over one year period,
in between January 2013 to December 2013. Informed written consent was
obtained from their legal guardians and/or children prior to the recruitment
and data collections. Study was approved by the ethical review committees of
BSMMU, Central Hospital Limited and University of Tsukuba Hospital.
2.4.1 DNA extraction and genotyping
Genetic DNA was extracted from 2ml peripheral blood of the patients
on maintenance therapy and volunteers using the Genomic DNA Isolation Kit
(QiAamp DNA Blood Mini Kit: Qiagen, Vealo, The Netherlands) following the
instructions from manufacturer. Polymorphisms of TPMT*3C(c.719A>G,
rs1142345), TPMT*2(c.238G>C, rs1800462), TPMT*3B(c.460G>A, rs1800460),
and ITPA(c.94C>A,rs1127354) were genotyped using the TaqMan
Assay-on-Demand SNP Typing System (Applied Bio Systems, Foster City, CA,
USA) following the manufacturer’s instructions. PCR was performed on a
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384-well format with 3ng of DNA each, and automatic allele calling was
performed using ABI PRISM 7900HT data collection and analysis software,
version 2.2.2 (Applied Biosystems).
2.4.2 Clinical and laboratory data collection
All relevant information such as demography of the participants, sign
and symptoms, disease state, toxicity profile and results of blood
biochemistries such as complete blood count, serum billirubin, liver
transaminases (ALT), and serum creatinine were documented. The worst
value of clinical and laboratory data were collected during maintenance
therapy. A maintenance therapy is given to prevent relapse and to achieve
total cure. Patients receive maintenance chemotherapy for 2 years with 6-MP,
methotrexate, vincristine and dexamethasone. 6-MP intolerance was defined
as the occurrence of hematopoietic toxicity, hepatotoxicity, and/other toxicities
that resulted in delays in subsequent chemotherapy. Hematologic toxicity was
defined as neutropenia, an absolute neutrophil count (ANC) <1.0X109/L.
Myelosuppression was defined as leucopenia, a reduction in the number of
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white cells (<3.0X109/L), and or thrombocytopenia (platelet count <100X109/L)
Hepatic toxicity was defined as a greater than two fold increase in serum
billirubin and ALT. Fever was defined as temperature >38.00 C. This toxicity
definition was set by my study group for this study purpose and usually used
by hematology and oncology department of BSMMU.
2.4.3 Statistical analysis
Statistical analysis was performed by using SPSS statistics version
21.0 (IBM Corporation, NY, USA). Data were expressed as number %, mean +
SD. Allele frequency was calculated by using Hardy-Weinberg principle.
Chi-square test was performed to compare the relationship between
polymorphism and development of toxicity.  Univariate and multivariate
logistic regression analysis was performed to see the effect of ITPA
polymorphism on toxicity. Two sided P value less than 0.05 were considered to
be statistically significant.
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2.5 Results
I enrolled 75 patients diagnosed with childhood ALL and 75 healthy
volunteer having age of (5 + 2.5) years and (3.1 + 1.6) years respectively;
86/150 (57.3%) were male (Table 1). TPMT and ITPA genetic polymorphism
were found in 6/150 (4%), and 34/150 (22.7%) respectively. For volunteers,
frequency of TPMT*3B (rs1800460), TPMT*3C (rs1142345), and ITPA94C>A
(rs1127354) polymorphism were 0.99, 0.98 and 0.90 respectively. For ALL
patients, frequency of TPMT*3C and ITPA94C>A were 0.98, and 0.87. I found
3 homozygous variant for ITPA94C>A (rs1127354) genes and no homozygous
variant for TPMT*3C, TPMT*3B and TPMT*2 alleles. All 3 homozygous
variant were among the ALL patients. I also found 31 heterozygous variant for
ITPA gene. ITPA94C>A was the most common variant in the subjects screened,
no TPMT*2 variant was detected (Table 2). The frequency of allele
ITPA94C>A, reported to be higher in the Asian population was 22.7% in
people of Bangladesh (in this study). This distribution is similar to those
reported in previous publication (24).
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It was observed that the ALL patients those who have TPMT*3C have
significantly higher chance of leucopenia (P=0.037), neutropenia (P=0.017)
and thrombocytopenia (P=0.008) .It has also been found that the ALL patients
those who have ITPA94C>A also have higher chance of neutropenia (P=0.001),
raised serum billirubin (P=0.048), raised ALT (P=0.007) and fever (P=0.003)
(table 3). In univariate logistic regression analysis, it was observed that ITPA
polymorphism had 6 times higher chance of absolute neutropenia (OR = 6.25,
95%CI = 2.01 – 19.42), 3 times higher chance of hyperbillirubinemia (OR =
3.58, 95% CI = 1.21 – 10.61), 4 times higher chance of increase ALT (OR = 4.53,
95% CI = 1.53 – 13.43) and 7 times higher chance of fever (OR = 7.00, 95% CI =
2.05 – 23.84) in compare to non-polymorphic patients. After adjusted with age,
sex, height and weight in multivariate logistic regression analysis the
association remained similar.
2.6 Discussion
The use of genomic sequence information for providing safe and
effective medication for developing “personalized/individualized medicine” is
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breezing the gap between the basic research and clinical practice (25). There
are no molecular analyses on Bangladeshi subjects to identify the
pharmacogenomics determinants of 6-MP associated drug toxicity. I conducted
this study because of growing interest in employing pharmacogenetics to
refine and better individualize treatment for childhood ALL. I determined the
laboratory parameters in ALL patients who were under maintenance phase of
the ALL treatment to correlate my results with clinical findings. Though my
study confirm the previous reports (5, 25), but it was important to
demonstrate these findings among Bangladeshi population.
TPMT is a gene, related to the anti-leukemia effects and side effects of
6-MP. It is mentioned as a potential gene selected for polymorphism testing
(26). Differences in TPMT polymorphism varies among different ethnic group,
it ranges from 2% to 14% prevalence (5). I found that allelic frequency of
TPMT*3C polymorphism among Bangladeshi was 3.3%, TPMT*3B was 0.7%,
although I did not find the TPMT*2 allele (table 2), most likely due to the
small sample size and the known low frequency of TPMT variants in Asian
population. The frequency and distribution of TPMT alleles in my study
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among Bangladeshi is similar to that of Iranian (27), Turkish (28) and
Japanese population (unpublished data).
The ITPA is an enzyme involve in the 6-MP metabolism. Genetic
polymorphisms in the ITPA gene are associated with reduced activity of the
ITPA enzyme and increased toxicity to 6-MP. There are several polymorphism
have been described for ITPA but the P32T (proline to threonine substitution
at amino acid 32) variant is the most common SNP (29). ITPA94C>A frequency
has been investigated in various populations. Studies on Asian population
including this study reveal a higher frequency of the variant allele than
American Caucasians (0.06) or British Caucasians (0.07) or African (0.05) (29,
30). Among Asian, Chinese was found to be (0.15), East Indian (0.11),
Philipino (0.14) (24), which reinforce my findings among Bangladeshi (0.22)
and Japanese population (unpublished data).
This is the first ever report from Bangladesh showing the effect of
TPMT and ITPA genotypes in optimizing 6-MP therapy based on genetic
constitution. Clinical consequence of one particular polymorphism is one of the
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major aspects about pharmacogenetics in the treatment outcomes. Several
previous studies indicate that TPMT polymorphisms are associated with 6-MP
toxicity (31, 32, 33). In my study, patients with predicted deficiency in ITPase,
tended to be more likely to develop fever, neutropenia and likely to experience
liver toxicity (raised serum billirubin and raised serum ALT) during treatment.
It was observed that all homozygous variant (AA) of ITPA allele were found
among ALL patients (4.0%). Study found that 6-MP toxicities tended to be
higher among homozygous and heterozygous variant allele of ITPA in compare
to wild type. I also found that TPMT*3C and TPMT*3B deficient patients are
more likely to develop myelosuppression such as neutropenia and
thrombocytopenia which is supported by previous findings (5, 34).
In my study, toxicity related to ITPA polymorphism was very high. It
may occur due to multiple causes. One possible explanation is low nutritional
status of the ALL patients in this study (BMI = 16.03 + 3.92). It has been well
known that undernourished children have higher chance of lower immunity
and increase chance of infections and toxicities or chemotherapy itself can
cause malnutrition and higher chance of toxicities (35). Other possible
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explanations are lack of regular monitoring of this group of children during
Chemotherapic treatment and higher dose of Chemotherapy which is
75mg/m2/day as per UKALL protocol (23) whereas Japanese start with lower
dose such as 40-50mg/m2 /day.
Limitation of the study: As with most genetic studies, my current
study was not sufficiently powered to derive definitive conclusion. Results of
this analysis showed that 2 cases out of 2 have shown hematological toxicities.
It might be due to small sample size and selection bias, and this is a major
limitation of this study. A larger sample size and well-designed study might
minimize the issue on statistical inference.
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2.7 Conclusions
The frequency of ITPA94C>A among Bangladeshi children is very high.
My results suggest that patients with TPMT and ITPA94C>A polymorphism
has higher chance of toxicity. My study strongly suggests the importance of
TPMT and ITPA genotyping in patients with ALL to design more rational and
cost effective treatment strategy in children with ALL. As ITPA is more
frequent in compare to TPMT among Bangladeshi population it should be
prioritize during screening process. My plan is to recommend stake holders
and policy maker to start genetic screening process before initiating the
Chemotherapic treatment for ALL children. It will minimize toxicities and
continue treatment and finally better outcomes of childhood ALL. I have also
plan to identify other associated conditions accompanying ALL such as Gilbert
syndrome. Furthermore, I recommend larger study for better findings of
TPMT allele frequency.
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Table 2.1: Baseline characteristics of the study participants
Characteristics ALL patients Volunteers
(mean + SD) (mean + SD)
Age (year) 5 + 2.5 3.1 + 1.6
Weight (kg) 17.62 + 7.74 14.10 + 4.02
Height (cm) 106.51 + 19.90 97.10 + 13.11
MUAC (cm) 15. 96 + 2.78 14.80 + 2.46
BMI 16.03 + 3.92
RBC count (X1012 /L) 3.27 + 0.48
WBC count (X109/L) 3.47 + 1.67
Neutrophil count (X109/L) 1.437 + 571
Platelet count (X109/L) 187 + 101
ALT (U/L) 59.09 + 54.08
Serum billirubin (µmol/L) 17.82 + 6.95
(n/%) (n/%)
Sex (male/female) 43/32 (28.7/21.3) 43/32 (28.7/21.3)
MUAC = Mid upper arm circumference, RBC = Red blood cell, WBC = White
blood cell, ALT = Alenine transaminases
SD = Standard deviation
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Table 2.2: Frequency of TPMT and ITPA alleles
Variations rs number Wild type Heterozygous Homozygous Minor
Allele
frequency
ALL patients
TPMT*2 rs1800462 75 0 0 0.000
TPMT*3B rs1800460 75 0 0 0.000
TPMT*3C rs1142345 73 2 0 0.010
ITPA94C>A rs1127354 55 17 3 0.153
Volunteers
TPMT*2 rs1800462 75 0 0 0.000
TPMT*3B rs1800460 74 1 0 0.006
TPMT*3C rs1142345 72 3 0 0.020
ITPA94C>A rs1127354 61 14 0 0.093
TPMT = thiopurine S-methyltransferase, ITPA=- inosine triphosphate
pyrophosphatase
Allele frequency was calculated by using Hardy-Weinberg principle
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Table 2.3: Relationship between clinical adverse event and polymorphism during
treatment with 6-MP in total 75 patients
Gene &  Genotype   Leuco- Neutro- Thrombo- Raised   Raised  Fever
location penia penia    cytopenia  billirubin  ALT
TPMT*3Cc.719A>G
AA 73          22        18 15          21          28      35
AG/GG 2           2          2 2           1           1       1
P-value 0.037      0.017     0.008 0.515       0.739   0.954
ITPAc.94C>A
CC 55          6          9          12          12          16       20
CA/AA 20          8          11         5           10          13       16
P-value 0.183 0.001 0.167 0.048 0.007   0.003
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Table 2.4: Univariate and multivariate logistic regression analysis which
showing the relationship between ITPA polymorphism and toxicity
Crude OR 95% CI Adjusted OR 95% CI
Leucopenia 1.62 0.56-4.72 2.18 0.65-7.23
(<3×109/L)
Absolute neutropenia 6.25 2.01-19.42 7.68 2.21-26.61
(<1.0×109/L)
Thrombocytopenia 1.19 0.36-3.96 1.11 0.33-3.77
(<100×109/L)
Hyperbillirubinemia 3.58 1.21-10.61 4.73 1.39-16.07
(>17.3µmol/L)
Raised serum ALT 4.53 1.53-13.43 4.73 1.52-14.68
(>36U/L)
Fever 7.00 2.05-23.84 6.89 1.99-23.91
(>38°C)
OR, Odds ratio; CI, Confidence interval. Adjusted by age, sex, height, and
weight.
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CHAPTER 3
CONCLUSION
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This research was conducted to detect the frequency of polymorphism
of TPMT and ITPA among children in Bangladesh and also to see the
relationship of genetic polymorphism with toxicity. Till to date, there is no
research focusing on the polymorphism of drug metabolizing gene and this is
the first ever pharmacogenetic study in Bangladeshi, so that, based on this
report more extensive study regarding the pharmacogenetic of Asians can be
conducted in future.
This research showed several important results. First, this research
confirmed that ITPA is more prevalent than TPMT among Bangladeshi
population. Second, this research indicated that TPMT*3C is more common
than TPMT*3B and there is no TPMT*2 among Bangladeshi. This research
also suggested that TPMT and ITPA variant significantly influence the risk of
toxicity. Myelosuppression and febrile neutropenia occurred in TPMT and
ITPA variant respectively.
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Pharmacogenetics provided a molecular approach which guides the
individualization of chemotherapy. This approach may reduce the toxicity and
increases safety of the therapy. In the treatment of ALL, the knowledge of
SNPs in 6-MP metabolizing enzymes and its related drug toxicity has
developed more rational approaches to optimize chemotherapy. TPMT and
ITPA genetic variant differ from patient to patient and among different ethnic.
Determination of the frequency of this genetic variant is necessary to consider
the use of pharmacogenetic as a tool to improve treatment outcome. This
research strongly suggests the importance of TPMT and ITPA genotyping in
patients with ALL to design more rational and cost effective treatment
strategy in children with ALL. As ITPA is more frequent in compare to TPMT
among Bangladeshi population it should be prioritize during screening process.
Furthermore, I recommend larger study for better findings of TPMT allele
frequency.
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